114
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study

ORCID Icon, , , & ORCID Icon
Pages 2119-2127 | Published online: 16 Jul 2021
 

Abstract

Background and Objective

Prescribing inhaled corticosteroids (ICS) for bronchiectasis (BE) in the absence of obstructive lung disease is controversial. Studies investigating ICS therapy and impact on morbidity and mortality in BE are sparse.

Methods

This study comprises all patients with BE managed at respiratory outpatient clinics at two university hospitals in the Capital Region of Denmark 2014–2015. Baseline data were obtained from patient medical records, and patients were followed until April 2020.

Results

Out of 264 patients, 122 (46%) were prescribed ICS with no demographic differences between users/non-users of ICS. Among patients prescribed ICS, 21% did not have a concomitant diagnosis of asthma or COPD. Patients prescribed ICS had lower lung function (median FEV1 65.2 vs 80.9%pred, p<0.001) and a higher symptom burden in terms of cough (p 0.028), sputum production (p <0.001) and dyspnea (p <0.001). Pseudomonas-positive sputum cultures were more common in ICS-treated patients (6.5 vs 20%, p 0.010), as were previous severe exacerbations (41% vs 21%, p <0.001). In terms of mortality, high-dose ICS use was associated with increased mortality in multivariable Cox regression adjusted for age, sex, FEV1 and concomitant asthma/COPD (HR 4.93 [95% CI 1.73–14.0], p 0.003).

Conclusion

In this cohort, close to one out of five patients with BE were prescribed ICS despite having no concomitant diagnosis of asthma or COPD. Overall, ICS treatment was associated with higher morbidity and mortality, though causation is difficult to establish.

Disclosure

KEJH reports personal fees from AstraZeneca, Chiesi and TEVA outside the present work. CSU reports personal fees from AstraZeneca, Chiesi, TEVA, Novartis, GSK, Orion Pharma, Actelion, ALK-Abello, Sanofi, and Boehringer-Ingelheim outside the present work. KF, AB and MS declare no conflicts of interest with regard to the present article.